BTK-IN-15
BTK-IN-15 (compound 42) is a potent Bruton's tyrosine kinase (BTK) inhibitor with high oral absorption. BTK-IN-15 inhibits BTK with an IC50 value of 0.7 nM. BTK-IN-15 displays excellent kinase selectivity, antitumor activity, and induces apoptosis.
For research use only. We do not sell to patients.
- CAS No.: 2820426-92-2
- Formula: C28H24FN5O2
- Molecular Weight:481.52
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
IC50: 0.7 nM (BTK)[1]
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| DOHH-2 | IC50 |
5.263 μM
Compound: 42
|
Antiproliferative activity against human DOHH-2 cells incubated for 72 hrs by CellTiter-Glo assay
Antiproliferative activity against human DOHH-2 cells incubated for 72 hrs by CellTiter-Glo assay
|
[PMID: 35939993] |
| OCI-Ly3 | IC50 |
>10 μM
Compound: 42
|
Antiproliferative activity against human OCILY3 cells incubated for 72 hrs by CellTiter-Glo assay
Antiproliferative activity against human OCILY3 cells incubated for 72 hrs by CellTiter-Glo assay
|
[PMID: 35939993] |
| Pfeiffer | IC50 |
>10 μM
Compound: 42
|
Antiproliferative activity against human Pfeiffer cells incubated for 72 hrs by CellTiter-Glo assay
Antiproliferative activity against human Pfeiffer cells incubated for 72 hrs by CellTiter-Glo assay
|
[PMID: 35939993] |
| Raji | IC50 |
>10 μM
Compound: 42
|
Antiproliferative activity against human Raji cells incubated for 72 hrs by CellTiter-Glo assay
Antiproliferative activity against human Raji cells incubated for 72 hrs by CellTiter-Glo assay
|
[PMID: 35939993] |
| Ramos | IC50 |
>10 μM
Compound: 42
|
Antiproliferative activity against human Ramos cells incubated for 72 hrs by CellTiter-Glo assay
Antiproliferative activity against human Ramos cells incubated for 72 hrs by CellTiter-Glo assay
|
[PMID: 35939993] |
| Rec1 | IC50 |
0.0017 μM
Compound: 42
|
Antiproliferative activity against human REC1 cells incubated for 72 hrs by CellTiter-Glo assay
Antiproliferative activity against human REC1 cells incubated for 72 hrs by CellTiter-Glo assay
|
[PMID: 35939993] |
| SUD4 | IC50 |
>10 μM
Compound: 42
|
Antiproliferative activity against human SU-DHL-4 cells incubated for 72 hrs by CellTiter-Glo assay
Antiproliferative activity against human SU-DHL-4 cells incubated for 72 hrs by CellTiter-Glo assay
|
[PMID: 35939993] |
| SU-DHL-6 | IC50 |
>10 μM
Compound: 42
|
Antiproliferative activity against human SU-DHL-6 cells incubated for 72 hrs by CellTiter-Glo assay
Antiproliferative activity against human SU-DHL-6 cells incubated for 72 hrs by CellTiter-Glo assay
|
[PMID: 35939993] |
| TMD8 | IC50 |
2.6 nM
Compound: 42
|
Antiproliferative activity against human TMD8 cells incubated for 72 hrs by CellTiter-Glo assay
Antiproliferative activity against human TMD8 cells incubated for 72 hrs by CellTiter-Glo assay
|
[PMID: 35939993] |
In Vitro
BTK inhibition is an effective approach against B-cell malignancies[1].
BTK-IN-15 (compound 42) demonstrates inhibitory against TMD8 with an IC50 value of 2.6 nM[1].
BTK-IN-15 (1 μM; 1 h) displays significant selectivity to BTK over EGFR kinase with 0.05% and 44% of the control, respectively[1].
BTK-IN-15 (0-1 mM; 72 h) exerts potent anti-proliferative activity against a human mantle cell lymphoma cell line (REC-1) with an IC50 value of 1.7 nM[1].
BTK-IN-15 (0-1 mM; 2 h) inhibits BTK auto-phosphorylation with an IC50 value of 1.49 nM[1].
BTK-IN-15 (0-100 nM; 48 h) arrests cell cycle at G1 phase and (0-1 mM; 72 h) induces apoptosis in TMD8[1].
BTK-IN-15 shows low hERG channel activity (IC50=4.38 μM), indicating low cardiotoxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:B-cell lymphoma (DLBCL) TMD8 cancer cells
-
Concentration:0, 0.15, 0.46, 1.37, 4.12, 12.35, 37.04, 111, 333, 1000 nM
-
Incubation Time:2 hours
-
Result:Inhibited BTK auto-phosphorylation at the Tyr223 site with an IC50 value of 1.49 nM.
-
Cell Line:B-cell lymphoma (DLBCL) TMD8 cancer cells
-
Concentration:0, 10, 100 nM
-
Incubation Time:48 hours
-
Result:Arrested cell cycle progression at G1 phase in a dose-dependent manner, the percentage of cells in the G0/G1 phase increased from 33.0 to 63.0% with a dose range of 1-100 nM.
-
Cell Line:B-cell lymphoma (DLBCL) TMD8 cancer cells
-
Concentration:0, 10, 100, 1000 nM
-
Incubation Time:72 hours
-
Result:Induced apoptosis of TMD8 cells in a weakly triggered concentration-dependent manner, with the apoptosis cell values of 19% (10 nM), 25.2% (100 nM), and 31.4% (1000 nM), respectively.
In Vivo
BTK-IN-15 (300, 400, 500 mg/kg; p.o.; twice daily; 14 d) has biological safety and displays no affect against body weight in mice compared with control[1].
BTK-IN-15 (10 mg/kg; p.o.) shows a high oral bioavailability of 40.98% in mice[1].
Pharmacokinetics of BTK-IN-15 in Mice[1]
| Route | Dose (mg/kg) | Tmax (h) | Cmax (ng/mL) | AUC(0-t) (h•ng/mL) | AUC(0-∞) (h•ng/mL) | T1/2 (h) | Vz (L/kg) | CL (L/h/kg) | F (%) |
| i.v. | 2 | 0.03 | 2245.39 | 1471.35 | 718.33 | 0.67 | 2.79 | 2.87 | 40.98 |
| p.o. | 10 | 0.39 | 1441.59 | 718.33 | 1472.06 | 0.59 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female CB-17 SCID nude mice with TMD8 xenograft model[1]
-
Dosage:12.5 mg/kg, 25 mg/kg, and 50 mg/kg
-
Administration:Oral gavage; twice daily; 21 days
-
Result:Inhibited tumor growth at a dosage of 50 mg/kg and reduced tumor volume after 21 days with a TGI of 104%.
Reduced the content of white blood cells, lymphocytes and monocytes, while showed no effect on red blood cell and platelets.
-
Animal Model:ICR mice (acclimation for 5 days, 18-20 g)[1]
-
Dosage:300, 400, 500 mg/kg
-
Administration:Oral gavage; 14 days
-
Result:Demonstrated no affect against body weight in mice compared with control.
Chemical Information
-
CAS No. 2820426-92-2
-
Molecular Weight 481.52
-
Formula C28H24FN5O2
-
SMILES
O=C(C=C)N1CCC(C2=CNC3=NC=NC(C4=CC=C(CNC(C5=CC=CC=C5)=O)C(F)=C4)=C23)=CC1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Detection of Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)